Join the Empaveli group to help and get support from people like you.
Empaveli News
FDA Approves Empaveli for Rare Kidney Diseases
FRIDAY, Aug. 1, 2025 – The U.S. Food and Drug Administration has approved Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative...
FDA Approves Apellis’ Empaveli (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) – Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved Empaveli (pegcetacoplan) ...
Apellis Announces U.S. FDA Approval of the Empaveli Injector, a Device to Streamline Self-Administration
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) – Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved the Empaveli® Injector. ...
FDA Approves Empaveli (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) – Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the U.S....